phase pnh updat similar prior data
limit commerci valu pnh nich
opportun seem possibl ra pharma announc complet
dose top-line data sc pnh program note
durabl effect treatment nave patient subject treat
week ldh level slightli uln think profil
fall short readout think thatespeci
ex-u marketsther may nich newli diagnos patient
prefer daili sc therapi npv program constrain low
pivot trial pnh commenc gmg phase readout
compani expect end-of-phas meet
fda first half year initi pivot trial pnh
skeptic compani abil creat signific valu
pnh see potenti brighter commerci outlook
complement indic gener myasthenia gravi
gmg patient us addit ex-
us could benefit daily-sc option attract price point
valuationmaintain outperform rate take tp
reduc us pnh project
gener optimist posit readout
expect less competit region stock trade close
cash level end activ lead compound think
compani may creat valu product data addit
indic outsid pnh gmg risk thesi includ
competit clinical/regulatori risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
ra pharma clinical-stag biopharma use proprietari peptid
chemistri platform develop novel therapeut treatment
price feb rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
assum price larg discount soliri
higher penetr gmg patient negative/mix
result pnh
unexpect safeti issu render uncompetit
charl martineau univers toronto updat scenario analysi scenario weight blend target price
per-share weight scenario tp
compani mention price
